LAMY engages in developing a business tapping the eLearning market and the gaming market by teaching financial knowledge and resource management to children. The company is headquartered in St. Petersburg, Florida. The company went IPO on 2024-04-30. The firm is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
Pure Transit Technologies Inc 주요 수익원은 Automotive Seating Supply이며, 최신 수익 발표에서 수익은 14,688,000,000입니다. 지역별로는 United States이 Pure Transit Technologies Inc의 주요 시장이며, 수익은 5,893,000,000입니다.
LAMY은 수익성이 있나요?
no, 최신 재무제표에 따르면 Pure Transit Technologies Inc의 순손실은 $-3입니다.
LAMY에 부채가 있나요?
no, Pure Transit Technologies Inc의 부채는 0입니다.
LAMY의 발행 주식은 몇 주인가요?
Pure Transit Technologies Inc의 총 발행 주식은 22.91주입니다.